Table 1 EB patients treated with cetuximab in the literature
Age at tumor’s presentation (years) | Tumor characteristics | Lymph node metastases present | Organ metastases present | Treatment options before cetuximaba | Patient outcome under cetuximab | Reference | |
|---|---|---|---|---|---|---|---|
1 | 29 | primary tumor on right forearm; axillary lymph node metastases as well as in-transit cutaneous metastases on the right upper limb | axillary | – | – | treatment initially well-tolerated, but wound healing deficits after 6 months; progression free survival for 9 months; treatment discontinuation after 2 years after grade 2 allergic reaction; death 1 year later after use of other treatment options | Medek et al., J Dtsch Dermatol Ges. 2019 |
2 | 24 | primary well-differentiated SCC on right elbow; subcutaneous metastasis next to SCC; tumor regrowth within weeks after 3x excisions (amputation declined by patient) | 2 axillary | – | radiotherapy; chemotherapy with cisplatin and 5-fluorouracil (2 cycles)> > chemotherapy with cisplatin and paclitaxel for 1 month> > cetuximab for 12 cycles | besides acneiform folliculitis on the face treatment well-tolerated; progression free survival for 3 months | Arnold et al., Dermatology, 2009 |
3 | 26 | moderately differentiated SCC on the dorsal right hand; quick tumor regrowth after excision, resulting in amputation | 2/22 axillary | lung | axillary dis-section followed by local radiotherapy> > cetuximab for 10 cycles> > due to progression of lung metastasis combination with gemcitabine | treatment well tolerated; death around 3 weeks after initiation of cetuximab+ gemcitabine treatment on pneumonia | Kim et al., Br J Dermatol. 2013 |
4 | 43 | well-differentiated SCC in axilla with extensive extranodal local spread; recurrence in axilla within 3 months after axillary node dissection | 6/16 axillary | lung | axillary dis-section followed by local radiotherapy; cetuximab for 7 cycles> > due to development of multiple lung metastases: methotrexate 40 mg orally and then i.v. for 9 weeks> > treatment cessation due to progressive disease | initially development of a vesicular eruption, no other side effects; death 2 months after treatment discontinuation on pneumonia | Kim et al., Br J Dermatol. 2013 |
5 | na | na | na | na | na | worsening of skin lesions | Maubec et al., J Clin Oncol. 2011 |